http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
프로필티오유라실 (Propylthiouracil)과 연관된 p-ANCA 양성 혈관염에 동반된 초점성 분절성 사구체 경화증
박윤경 ( Yoon Kyung Park ),윤여욱 ( Yeo Wook Yun ),성상석 ( Sang Suk Sung ),박의순 ( Ui Soon Park ),박성현 ( Sung Hyun Park ),우진현 ( Jin Hyun Woo ),박재일 ( Jae Il Park ),장선주 ( Sun Joo Jang ),한상웅 ( Sang Woong Han ),오영하 대한신장학회 2004 Kidney Research and Clinical Practice Vol.23 No.6
만성 신장병 환자에서 레닌-안지오텐신계 억제제와 칼륨교환수지 동시 사용이 혈청 칼륨에 미치는 영향
이주학 ( Joo Hark Yi ),윤여욱 ( Yeo Wook Yun ),노유석 ( U Seok Noh ),김은영 ( Eun Young Kim ),박재일 ( Jae Il Park ),한상웅 ( Sang Woong Han ),김호중 ( Ho Jung Kim ) 대한신장학회 2007 Kidney Research and Clinical Practice Vol.26 No.5
Purpose : This prospective study aimed to evaluate the safety and efficacy of potassium-exchange resin (PER, Kalimateⓡ or Argamateⓡ) for managing hyperkalemia induced by Renin-Angiotensin System (RAS) blockers in chronic kidney disease (CKD) patients without their discontinuation. Methods : Besides conservative remedies including low-potassium diet, all hyperkalemic CKD patients (n=21, [K] ≥5.6 mEq/L) received PER added on angiotensin-converting enzyme inhibitor (Moexipril, n=2) or angiotensin-receptor blocker (Irbesartan, n=19) with, at least, weekly monitoring of serum [K] if its level remains more than 5.5 mEq/L for more than 2 months (mean±SD, 6.8±5.9 mon; range, 2-26 mon). Results : Baseline serum [K] on RAS blocker alone (5.1±0.4 mEq/L; 4.2-6.3 mEq/L) increased to 6.0 ±0.4 mEq/L (p<0.05) before adding PER, and then it was significantly decreased to 5.3±0.6 mEq/L at the first clinic visit (p<0.05) and to 5.0±0.7 mEq/L at the last clinic visit (p<0.05) following the administration of PER added on RAS blocker. During the study period, GFR, serum creatinine and urinary protein excretion didn`t change significantly. Conclusion : The development of hyperkalemia on RAS blockers in CKD patients doesn`t necessarily lead to withdrawal of RAS blockers when the cautious add-on therapy of potassium-exchange resin with other conservative remedies launches, unless severe refractory hyperkalemia persists. II type 1 receptor blockers
Fanconi 증후군으로 발현한 Chinese Herb Nephropathy - 서양형과 동양형의 차이 비교 -
최창렬 ( Chang Ryeol Choi ),윤여욱 ( Yeo Wook Yun ),이동규 ( Dong Kyu Lee ),정재면 ( Jae Myun Jung ),홍택원 ( Taeck Won Hong ),한상웅 ( Sang Woong Han ),백승삼 ( Seung Sam Paik ),박문향 ( Moon Hyang Park ),김호중 ( Ho Jung Kim 대한신장학회 2003 Kidney Research and Clinical Practice Vol.22 No.1
We encountered one case of Chinese Herb Nephropathy in Korea. But clinical feature of our case was different from those of CHN in Belgium. The purpose of this case report was clarified the features of CHN in Asia. The subjects consisted of a patient diagnosed as interstitial nephritis in Hanyang University Hospital and of those reported in the literature in Asia and Belgium. We investigated the clinical and histological features of CHN patients in Asia and compared them with the Belgian cases. The renarkable differences were as follows; (1) relatively high prevalence in males compared with Belgian cases, (2) digestion with multiple object and mode in Asia, (3) Most of renal failure in Asia were improved or were in stable status, (4) Fanconi`s syndrome was found in most cases of Asia. In conclusion, CFN in Asia has some characteristics distinguished from Belgian Chinese Hreb Nephropathy. These findings could indicate that susceptibility to aristolochic acid may be different among races. Furthermore, it is likely that different components of AA could cause different features, that the amount of ingested AA, mode in digestion, or interaction with other components except nephrotoxic agent such as AA might reflect clinical pictures. Other hypothesis may be some other toxic substances affecting the clinical findings although they are not identified at present. further studies must be underaken to clarify these diferences.